Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology

European Journal of Cancer Part A

Volumn 33, Issue 2, 1997, Pages 232-237

  Gentet, J C ^a   Brunat Mentigny, M ^b   Demaille, M C ^c   Pein, F ^d   Avet Loiseau, H ^e   Berger, C ^f   De Lumley, L ^g   Pacquement, H ^h   Schmitt, C ⁱ   Sariban, E ^j   Pillon, P ^a   Bernard, J L ^a   Kalifa, C ^d  

^a Children's Hospital   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL NORD   (France)

^g DUPUYTREN UNIVERSITY HOSPITAL   (France)

^h INSTITUT CURIE   (France)

ⁱ HÔPITAL D ENFANTS   (France)

^j HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

more..

Author keywords

Chemotherapy; Children; Etoposide; Ifosfamide; Osteosarcoma

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030995153     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00439-X     Document Type: Article

References (22)

1. De Kracker J, Voute PA. Ifosfamide and vincristine in pediatric tumors. A pediatric phase II study. Eur Pediatr Hematol Oncol 1984, 1, 47-50.
2. Pinkerton DR, Rogers H, James C, et al. A phase II study of ifosfamide in children with recurrent solid tumors. Cancer Chemother Pharmacol 1985, 15, 258-262.
3. Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant tumors. Cancer Treat Rep 1987, 71, 131-135.
4. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987, 5, 1191-1198.
5. Kung FH, Pratt CB, Bernstein M, Vega RA. Ifosfamide/ Etoposide combination in the treatment of recurrent malignant solid tumors of childhood. Cancer 1993, 71, 1898-1903.
6. EORTC Clinical Screening Group. VP16 in treatment of acute leukemias, haematosarcomas and solid tumors. Br Med J 1973, 3, 199-202.
7. Nissen NI, Pajak TF, Leone LA, et al. Clinical trial of VP16 IV twice weekly in advanced neoplastic disease. Cancer 1980, 45, 232-235.
8. Kung FH, Haves FA, Kirscher J, et al. Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs 1988, 6, 31-36.
9. Marti C, Kroner T, Remagen W, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985, 69, 115-117.
10. Bowman LC, Meyer WH, Douglass EC, et al. Activity of ifosfamide in metastatic and unresectable osteosarcoma. Proc Am Soc Clin Oncol 1987, 6, 214 (abstract).
11. Meyer WH, Pratt CB, Parham D, et al. The activity of ifosfamide in previously untreated patients with osteosarcoma: preliminary results of the SJCRH OS-86 study. Proc Am Soc Clin Oncol 1988, 7, 261 (abstract).
12. Chawla SP, Rosen G, Lowenbraun S, et al. Role of high dose ifosfamide in recurrent osteosarcoma. Proc Am Soc Clin Oncol 1990, 9, 310 (abstract).
13. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response on pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group Study. Med Ped Oncol 1995, 24, 87-92.
14. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987, 5, 1191-1198.
15. Bacci G, Picci P, Avella M, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma. A retrospective analysis of high-dose methotrexate, cisplatinum and adriamycine used preoperatively. J Chemother 1990, 2, 127-135.
16. Bacci G, Picci P, Pignatti G, et al. Neoadjuvant chemotherapy for non metastatic osteosarcoma of the extremities. Clin Orthop 1991, 270, 87-98.
17. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy for osteosarcoma: results of a randomised cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988, 6, 329.
18. World Health Organisation. Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Nijhoff, The Hague, The Netherlands, 1979.
19. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961, 13, 346-356.
20. Epelman S, Seibel N, Melaragno R, et al. Treatment of newly diagnosed high grade osteosarcoma with ifosfamide, adriamycin and cisplatin without high dose methotrexate. Proc Am Soc Clin Oncol 1995, 14, 439 (abstract).
21. Le Cesne A, Fizazi K, De Balincourt C, et al. Intensive induction chemotherapy without methotrexate in adult patients with osteosarcoma. A feasibility study. Proc Am Soc Clin Oncol 1995, 14, 519 (abstract).
22. Benjamin RS, Patel SR, Armen T, et al. The value of ifosfamide in postoperative neoadjuvant chemotherapy of osteosarcoma. Proc Am Soc Clin Oncol 1995, 14, 516 (abstract).